Oxycodone

Dose and dosing frequency are the dominant determinants of how long oxycodone remains detectable. A single therapeutic dose of immediate-release oxycodone is generally cleared from urine within roughly 24 to 48 hours at a 100 ng/mL cutoff. Patients on chronic extended-release oxycodone for cancer or non-cancer pain may produce a positive screen for 3 to 4 days after their last dose because steady-state exposure produces higher residual metabolite concentrations and because the controlled-release matrix extends absorption. The metabolite noroxycodone typically persists slightly longer than parent oxycodone, which is why most modern assays detect either or both.

Route of administration affects pharmacokinetics. Oral oxycodone — the licensed route for all FDA-approved formulations — undergoes significant first-pass hepatic metabolism with an oral bioavailability of roughly 60–87%. Non-medical use by insufflation, smoking, or injection bypasses first-pass metabolism, producing higher peak plasma concentrations and a different metabolite ratio that confirmation laboratories can sometimes identify. Magenta does not provide guidance on non-medical routes; for clinical and forensic purposes, the relevant point is that route changes peak concentration and clearance kinetics in ways that may modify the screening window at the margins.

Hepatic function is critical because oxycodone is metabolized primarily through CYP3A4 with a contribution from CYP2D6. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, and grapefruit juice in some patients) raise plasma oxycodone concentrations and can extend the urinary detection window. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) accelerate clearance and can shorten it. CYP2D6 polymorphism affects oxymorphone production: poor metabolizers produce less oxymorphone, and ultra-rapid metabolizers produce more, which can shift the parent-to-metabolite ratio on confirmation testing. Significant hepatic impairment from cirrhosis or hepatitis prolongs clearance overall.

Renal function influences excretion of oxycodone and its metabolites. Noroxycodone and oxymorphone are renally cleared, and impaired renal function extends their urinary detection. Age, body composition, hydration status, and concurrent medications all contribute smaller modifying effects. Heavily dilute urine — by accident or by intent — lowers the concentration of all analytes and may produce a false negative at the cutoff; federal and most non-federal programs use creatinine and specific-gravity testing to flag dilute specimens for recollection rather than accepting them as negative.

Under SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs, oxycodone has been included as a separate analyte since the 2017 revision, distinct from the legacy opiate (morphine/codeine) panel. The federal screening cutoff for oxycodone in urine is 100 ng/mL, with the same 100 ng/mL cutoff used for confirmation by gas chromatography/mass spectrometry (GC/MS) or liquid chromatography/tandem mass spectrometry (LC-MS/MS). The expanded panel also added oxymorphone, hydrocodone, and hydromorphone, each at a 100 ng/mL screening cutoff.

Non-federal workplace and clinical programs are free to set their own cutoffs, and many do. Pain-management and substance-use-disorder treatment settings sometimes use lower cutoffs (50 ng/mL or below) for greater sensitivity to non-adherence or diversion in chronic-opioid-therapy patients. Magenta's CLIA-waived oxycodone dip cards and the oxycodone analyte on our multi-panel cups are calibrated at the industry-standard 100 ng/mL cutoff by default; talk to us about custom cutoffs for clinical or specialty applications.

Critically, the SAMHSA-5 panel's opiate immunoassay at 2000 ng/mL will not reliably detect therapeutic-range oxycodone use. Programs that intend to monitor oxycodone must include a dedicated oxycodone-specific assay — either as a stand-alone dip card or as part of a multi-panel device that includes oxycodone. A presumptive negative on a generic opiate immunoassay does not establish the absence of oxycodone.

Oxycodone urinary immunoassays use the lateral-flow competitive-binding format common to all Magenta point-of-care devices. The test strip contains a membrane impregnated with anti-oxycodone antibodies and a colored conjugate. When urine wicks up the strip, free oxycodone and cross-reactive metabolites from the sample compete with the labeled conjugate for antibody binding sites. If oxycodone is present at or above the 100 ng/mL cutoff, it occupies enough antibody binding sites that the conjugate cannot accumulate at the test line, producing a negative-line, positive-result pattern. The control line confirms reagents are working. Read time is typically five minutes.

Cross-reactivity is a particular concern for oxycodone immunoassays because the dedicated oxycodone antibody is intentionally designed to react with closely related compounds, but the breadth of that reactivity varies by manufacturer. Most modern oxycodone immunoassays cross-react with oxymorphone (the active CYP2D6 metabolite of oxycodone) at concentrations near the cutoff, which is clinically appropriate because oxymorphone is both a metabolite and a separately prescribed analgesic (Opana). Cross-reactivity with hydrocodone and hydromorphone is variable; some assays detect them, others do not. The package insert lists the specific cross-reactive compounds and the concentrations at which they produce a positive screen.

The legacy opiate (OPI) immunoassay at the SAMHSA 2000 ng/mL cutoff is calibrated against morphine and codeine and has historically poor cross-reactivity with oxycodone at therapeutic-range concentrations. This is precisely why SAMHSA added oxycodone as a separate analyte in its 2017 expanded panel and why programs monitoring oxycodone-using populations must select a panel that explicitly includes an oxycodone-specific assay rather than relying on the generic OPI screen. False negatives on legacy panels were a documented problem in pain-management and opioid-treatment settings for years before the expanded panel became widely available.

Confirmation testing by GC/MS or LC-MS/MS is the gold standard for resolving any presumptive positive. These instrumental methods identify oxycodone, noroxycodone, and oxymorphone by their specific mass spectra and quantify each precisely, distinguishing oxycodone from cross-reactive compounds. SAMHSA-certified laboratories perform confirmation on every presumptive positive in federal programs, and a Medical Review Officer (MRO) reviews confirmed positives against the donor's prescription history. A valid prescription for oxycodone, oxymorphone, hydrocodone, or hydromorphone is generally a legitimate medical explanation for a positive result, though MROs assess use patterns and consistency with the prescribed regimen.

Specimen validity testing should accompany every oxycodone screen. Creatinine, specific gravity, pH, and oxidant adulterant panels identify dilute or adulterated specimens. Because oxycodone is most commonly tested in pain-management, substance-use treatment, and workplace settings — populations with varying baseline urine characteristics — sample-handling protocols should provide for repeat collection when specimens fall outside validity parameters rather than immediately classifying the result as a refusal to test. Magenta's adulteration-panel cups include integrated creatinine, pH, specific gravity, glutaraldehyde, nitrite, and oxidant test pads.